RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Quantum Genomics Net Income 2024

Quantum Genomics Net Income

301.04 M EUR

Quantum Genomics Dividend yield

Ticker

ALQGC.PA

ISIN

FR0011648971

WKN

A1XAEB

In 2024, Quantum Genomics's profit amounted to 301.04 M EUR, a -9,593.65% increase from the -3.17 M EUR profit recorded in the previous year.

The Quantum Genomics Net Income history

YEARNET INCOME (undefined EUR)
2026e1.41
2025e0.56
2024e0.3
2023-0
2022-0.02
2021-0.02
2020-0.01
2019-0.01
2018-0.01
2017-0.01
2016-0.01
2015-0
2014-0
2013-0
2012-0
2011-0
2010-0
2009-0
2008-0

Quantum Genomics Aktienanalyse

What does Quantum Genomics do?

Quantum Genomics SA is a French biotechnology company focused on the discovery and development of novel therapies for the treatment of cardiovascular diseases. The company was founded in 2005 in Grenoble, France, where its headquarters are still located. Over 25 employees are currently working on the development of new drugs. The business model of Quantum Genomics SA is based on the research and development of new and innovative solutions for the cardiovascular disease market. The company focuses on a new class of drugs that target the brain to lower blood pressure and treat certain cardiovascular diseases. The goal of these new therapies is to improve the effectiveness of existing treatment methods by directly addressing the causes of the disease. Quantum Genomics SA has established partnerships with renowned research institutes and universities. The collaboration with these institutions aims to accelerate and intensify the research and development of new drugs. Through this collaboration, the company will be able to develop new solutions and therapies to treat cardiovascular diseases at a faster pace. The company is currently working on two main products: Firibastat and the QT-Glutamylcyclotransferase inhibitor. Firibastat is an oral medication developed for the treatment of hypertension. The QT-Glutamylcyclotransferase inhibitor is another medication that is intended to lower blood pressure. These are promising new solutions that can enable Quantum Genomics SA to play a significant role in the cardiovascular disease market. The products of Quantum Genomics SA aim to treat cardiovascular diseases better and more effectively by directly targeting the brain. This aims to reduce the risk of serious complications and side effects that may occur with conventional medications. In recent years, Quantum Genomics SA has received several awards, including the "Innovation Prize" from the French government. These awards demonstrate that the company is on the right track and achieving its goals. Overall, Quantum Genomics SA has a promising business model based on the development of new therapies for the treatment of cardiovascular diseases. With collaborations with renowned research institutes and the development of promising new products, the company is well-positioned to be successful and make significant progress in the growing market of cardiovascular diseases. Quantum Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Quantum Genomics's Profit Margins

The profit margins of Quantum Genomics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Quantum Genomics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Quantum Genomics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Quantum Genomics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Quantum Genomics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Quantum Genomics Stock

How much profit has Quantum Genomics made this year?

Quantum Genomics has made 301.04 M EUR this year.

How has the profit developed compared to last year?

The profit has increased by -9,593.65% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Quantum Genomics publish its earnings?

Quantum Genomics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Quantum Genomics?

The profits of Quantum Genomics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Quantum Genomics?

You can learn more about the earnings of Quantum Genomics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Quantum Genomics pay?

Over the past 12 months, Quantum Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Quantum Genomics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Quantum Genomics?

The current dividend yield of Quantum Genomics is .

When does Quantum Genomics pay dividends?

Quantum Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Quantum Genomics?

Quantum Genomics paid dividends every year for the past 0 years.

What is the dividend of Quantum Genomics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Quantum Genomics located?

Quantum Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Quantum Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Quantum Genomics from 5/15/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/15/2024.

When did Quantum Genomics pay the last dividend?

The last dividend was paid out on 5/15/2024.

What was the dividend of Quantum Genomics in the year 2023?

In the year 2023, Quantum Genomics distributed 0 EUR as dividends.

In which currency does Quantum Genomics pay out the dividend?

The dividends of Quantum Genomics are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Quantum Genomics

Our stock analysis for Quantum Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Quantum Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.